Plasma lipids during chronic antihypertensive therapy with different β-blockers

Roberto Fogari, Annalisa Zoppi, Carlo Pasotti, Luigi Poletti, Franco Tettamanti, Giandomenico Malamani, Luca Corradi

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The aim of this study was to compare the effects of long-term monotherapy with five different (β-blockers on plasma lipids in patients with essential hypertension. We studied 99 male patients, aged 35-55 years, with mild to moderate hypertension, who worked in the same community. After a 1-month placebo period, patients were assigned to receive propranolol (160 mg/ day), atenolol (100 mg/day), bisoprolol (10 mg/day), me-pindolol (10 mg/day), or celiprolol (400 mg/day). Therapy was continued for 2 years. Blood pressure (BP), heart rate, and blood samples for evaluation of total cholesterol (TC), LDL-cholesterol (LDL-C), triglycerides (TG) and HDL-cholesterol (HDL-C) were taken before and after the initial placebo period, and subsequently every 6 months from the beginning of active treatment. All p-blockers caused similar reductions in BP that were maintained throughout the study. None of the P-blockers significantly affected TC or LDL-C. Propranolol, a nonselective β -blocker, caused the most pronounced changes in TG (+ 33 to 43%) and in HDL-C (- 30 to - 32%). Atenolol, a prselective agent, had the same quantitative effects, but to a lesser extent (TG + 23 to 30%; HDL-C -15 to -19%). Bisoprolol, more Pi-selective than atenolol, and mepindolol, nonselective with ISA, increased TG (+ 20 to 28% and +14 to 25%, respectively) but did not significantly affect HDL-C. In contrast, celiprolol, a highly cardioselective p-blocker with β2-partial agonism, improved lipid risk factors by significantly reducing TG (-14 to - 21%) and increasing HDL-C (+ 8 to 14%). The change in HDL-C and TG caused by the different β-blockers appeared to be related to the ancillary properties of the different agents.

Original languageEnglish
Pages (from-to)S28-S32
JournalJournal of Cardiovascular Pharmacology
Volume14
Publication statusPublished - 1989

Fingerprint

HDL Cholesterol
Antihypertensive Agents
Bisoprolol
Triglycerides
Atenolol
Lipids
Celiprolol
Propranolol
LDL Cholesterol
Placebos
Blood Pressure
Therapeutics
Pindolol
Heart Rate
Cholesterol
Hypertension

Keywords

  • Atenolol
  • Bisoprolol
  • Celiprolol
  • Cholesterol
  • Mepindolol
  • Propranolol
  • Triglycerides

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Fogari, R., Zoppi, A., Pasotti, C., Poletti, L., Tettamanti, F., Malamani, G., & Corradi, L. (1989). Plasma lipids during chronic antihypertensive therapy with different β-blockers. Journal of Cardiovascular Pharmacology, 14, S28-S32.

Plasma lipids during chronic antihypertensive therapy with different β-blockers. / Fogari, Roberto; Zoppi, Annalisa; Pasotti, Carlo; Poletti, Luigi; Tettamanti, Franco; Malamani, Giandomenico; Corradi, Luca.

In: Journal of Cardiovascular Pharmacology, Vol. 14, 1989, p. S28-S32.

Research output: Contribution to journalArticle

Fogari, R, Zoppi, A, Pasotti, C, Poletti, L, Tettamanti, F, Malamani, G & Corradi, L 1989, 'Plasma lipids during chronic antihypertensive therapy with different β-blockers', Journal of Cardiovascular Pharmacology, vol. 14, pp. S28-S32.
Fogari R, Zoppi A, Pasotti C, Poletti L, Tettamanti F, Malamani G et al. Plasma lipids during chronic antihypertensive therapy with different β-blockers. Journal of Cardiovascular Pharmacology. 1989;14:S28-S32.
Fogari, Roberto ; Zoppi, Annalisa ; Pasotti, Carlo ; Poletti, Luigi ; Tettamanti, Franco ; Malamani, Giandomenico ; Corradi, Luca. / Plasma lipids during chronic antihypertensive therapy with different β-blockers. In: Journal of Cardiovascular Pharmacology. 1989 ; Vol. 14. pp. S28-S32.
@article{5a8a4aa4dbc6468a8c5f21708042e6b2,
title = "Plasma lipids during chronic antihypertensive therapy with different β-blockers",
abstract = "The aim of this study was to compare the effects of long-term monotherapy with five different (β-blockers on plasma lipids in patients with essential hypertension. We studied 99 male patients, aged 35-55 years, with mild to moderate hypertension, who worked in the same community. After a 1-month placebo period, patients were assigned to receive propranolol (160 mg/ day), atenolol (100 mg/day), bisoprolol (10 mg/day), me-pindolol (10 mg/day), or celiprolol (400 mg/day). Therapy was continued for 2 years. Blood pressure (BP), heart rate, and blood samples for evaluation of total cholesterol (TC), LDL-cholesterol (LDL-C), triglycerides (TG) and HDL-cholesterol (HDL-C) were taken before and after the initial placebo period, and subsequently every 6 months from the beginning of active treatment. All p-blockers caused similar reductions in BP that were maintained throughout the study. None of the P-blockers significantly affected TC or LDL-C. Propranolol, a nonselective β -blocker, caused the most pronounced changes in TG (+ 33 to 43{\%}) and in HDL-C (- 30 to - 32{\%}). Atenolol, a prselective agent, had the same quantitative effects, but to a lesser extent (TG + 23 to 30{\%}; HDL-C -15 to -19{\%}). Bisoprolol, more Pi-selective than atenolol, and mepindolol, nonselective with ISA, increased TG (+ 20 to 28{\%} and +14 to 25{\%}, respectively) but did not significantly affect HDL-C. In contrast, celiprolol, a highly cardioselective p-blocker with β2-partial agonism, improved lipid risk factors by significantly reducing TG (-14 to - 21{\%}) and increasing HDL-C (+ 8 to 14{\%}). The change in HDL-C and TG caused by the different β-blockers appeared to be related to the ancillary properties of the different agents.",
keywords = "Atenolol, Bisoprolol, Celiprolol, Cholesterol, Mepindolol, Propranolol, Triglycerides",
author = "Roberto Fogari and Annalisa Zoppi and Carlo Pasotti and Luigi Poletti and Franco Tettamanti and Giandomenico Malamani and Luca Corradi",
year = "1989",
language = "English",
volume = "14",
pages = "S28--S32",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Plasma lipids during chronic antihypertensive therapy with different β-blockers

AU - Fogari, Roberto

AU - Zoppi, Annalisa

AU - Pasotti, Carlo

AU - Poletti, Luigi

AU - Tettamanti, Franco

AU - Malamani, Giandomenico

AU - Corradi, Luca

PY - 1989

Y1 - 1989

N2 - The aim of this study was to compare the effects of long-term monotherapy with five different (β-blockers on plasma lipids in patients with essential hypertension. We studied 99 male patients, aged 35-55 years, with mild to moderate hypertension, who worked in the same community. After a 1-month placebo period, patients were assigned to receive propranolol (160 mg/ day), atenolol (100 mg/day), bisoprolol (10 mg/day), me-pindolol (10 mg/day), or celiprolol (400 mg/day). Therapy was continued for 2 years. Blood pressure (BP), heart rate, and blood samples for evaluation of total cholesterol (TC), LDL-cholesterol (LDL-C), triglycerides (TG) and HDL-cholesterol (HDL-C) were taken before and after the initial placebo period, and subsequently every 6 months from the beginning of active treatment. All p-blockers caused similar reductions in BP that were maintained throughout the study. None of the P-blockers significantly affected TC or LDL-C. Propranolol, a nonselective β -blocker, caused the most pronounced changes in TG (+ 33 to 43%) and in HDL-C (- 30 to - 32%). Atenolol, a prselective agent, had the same quantitative effects, but to a lesser extent (TG + 23 to 30%; HDL-C -15 to -19%). Bisoprolol, more Pi-selective than atenolol, and mepindolol, nonselective with ISA, increased TG (+ 20 to 28% and +14 to 25%, respectively) but did not significantly affect HDL-C. In contrast, celiprolol, a highly cardioselective p-blocker with β2-partial agonism, improved lipid risk factors by significantly reducing TG (-14 to - 21%) and increasing HDL-C (+ 8 to 14%). The change in HDL-C and TG caused by the different β-blockers appeared to be related to the ancillary properties of the different agents.

AB - The aim of this study was to compare the effects of long-term monotherapy with five different (β-blockers on plasma lipids in patients with essential hypertension. We studied 99 male patients, aged 35-55 years, with mild to moderate hypertension, who worked in the same community. After a 1-month placebo period, patients were assigned to receive propranolol (160 mg/ day), atenolol (100 mg/day), bisoprolol (10 mg/day), me-pindolol (10 mg/day), or celiprolol (400 mg/day). Therapy was continued for 2 years. Blood pressure (BP), heart rate, and blood samples for evaluation of total cholesterol (TC), LDL-cholesterol (LDL-C), triglycerides (TG) and HDL-cholesterol (HDL-C) were taken before and after the initial placebo period, and subsequently every 6 months from the beginning of active treatment. All p-blockers caused similar reductions in BP that were maintained throughout the study. None of the P-blockers significantly affected TC or LDL-C. Propranolol, a nonselective β -blocker, caused the most pronounced changes in TG (+ 33 to 43%) and in HDL-C (- 30 to - 32%). Atenolol, a prselective agent, had the same quantitative effects, but to a lesser extent (TG + 23 to 30%; HDL-C -15 to -19%). Bisoprolol, more Pi-selective than atenolol, and mepindolol, nonselective with ISA, increased TG (+ 20 to 28% and +14 to 25%, respectively) but did not significantly affect HDL-C. In contrast, celiprolol, a highly cardioselective p-blocker with β2-partial agonism, improved lipid risk factors by significantly reducing TG (-14 to - 21%) and increasing HDL-C (+ 8 to 14%). The change in HDL-C and TG caused by the different β-blockers appeared to be related to the ancillary properties of the different agents.

KW - Atenolol

KW - Bisoprolol

KW - Celiprolol

KW - Cholesterol

KW - Mepindolol

KW - Propranolol

KW - Triglycerides

UR - http://www.scopus.com/inward/record.url?scp=0024816646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024816646&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - S28-S32

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

ER -